Journal ArticleDOI
Natural history of chronic hepatitis B: Special emphasis on disease progression and prognostic factors
TLDR
There is a growing understanding of viral, host and environmental factors influencing disease progression, which ultimately could improve the management of chronic hepatitis B.About:
This article is published in Journal of Hepatology.The article was published on 2008-02-01. It has received 1172 citations till now. The article focuses on the topics: HBeAg & Hepatitis B.read more
Citations
More filters
Journal ArticleDOI
Monotherapy for hepatitis B infection: a review of treatment options
Resat Ozaras,Hawa'a Khodor,Nergul Yetim,Umut Kaan Unal,Yunus Emre Demirhan,Goknil Gultekin,Burak Isal +6 more
TL;DR: Long-term use of NUCs with maintained viral suppression results in a decrease in liver-related complications and Entecavir and tenofovir, with their high potency, high genetic barrier to resistance and favorable safety profile are the standard of care in CHB treatment.
Journal ArticleDOI
Comparison of telbivudine efficacy in treatment-naive patients with hepatitis B virus-related compensated and decompensated cirrhosis in 96 weeks.
TL;DR: Long-term LdT treatment showed superior virological, biochemical, and clinical efficacy in the compensated cirrhotic patients, and emphasized the importance of early antiviral treatment, which may improve the prognosis of cirrhosis patients.
Journal ArticleDOI
The FIB-4 Index Is a Useful Predictor for the Development of Hepatocellular Carcinoma in Patients with Coexisting Nonalcoholic Fatty Liver Disease and Chronic Hepatitis B.
TL;DR: In this paper, the authors analyzed the clinical association of the FIB-4 index with HCC development in patients with coexisting nonalcoholic fatty liver disease and chronic hepatitis B (NAFLD-CHB).
Hepatitis B: Screening, Awareness, and the Need to Treat.
Shilpa Lingala,Marc G. Ghany +1 more
TL;DR: Despite the availability of an effective hepatitis B vaccine, the global prevalence has not substantially declined, and significant barriers remain to screening and care.
Journal ArticleDOI
Do the circulating Pre-S/S quasispecies influence hepatitis B virus surface antigen levels in the HBeAg negative phase of HBV infection?
Daniela Cavallone,G. Ricco,Filippo Oliveri,Piero Colombatto,F. Moriconi,Barbara Coco,Veronica Romagnoli,A. Salvati,Lidia Surace,Ferruccio Bonino,Maurizia Rossana Brunetto,Maurizia Rossana Brunetto +11 more
TL;DR: Virus, host factors and their interplay influence Hep atitis B surface Antigen serum levels during Hepatitis B Virus infection course and treatment.
References
More filters
Journal ArticleDOI
Measuring inconsistency in meta-analyses
TL;DR: A new quantity is developed, I 2, which the authors believe gives a better measure of the consistency between trials in a meta-analysis, which is susceptible to the number of trials included in the meta- analysis.
Journal ArticleDOI
Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level.
Chien-Jen Chen,Hwai I. Yang,Jun Su,C.-L. Jen,San Lin You,Sheng-Nan Lu,Guan-Tarn Huang,Uchenna H. Iloeje +7 more
TL;DR: Elevated serum HBV DNA level (> or =10,000 copies/mL) is a strong risk predictor of hepatocellular carcinoma independent of HBeAg, serum alanine aminotransferase level, and liver cirrhosis.
Journal ArticleDOI
Chronic hepatitis B
Anna S. Lok,Brian J. McMahon +1 more
TL;DR: These guidelines have been written to assist physicians and other health care providers in the recognition, diagnosis, and management of patients chronically infected with the hepatitis B virus (HBV).
Journal ArticleDOI
The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide
TL;DR: HBV and HCV infections account for the majority of cirrhosis and primary liver cancer throughout most of the world, highlighting the need for programs to prevent new infections and provide medical management and treatment for those already infected.
Journal ArticleDOI
Hepatocellular carcinoma in cirrhosis: incidence and risk factors.
TL;DR: Further studies are needed to investigate other viral factors (eg, HBV genotype/mutant, occult HBV, HIV coinfection) and preventable or treatable comorbidities ( eg, obesity, diabetes) in the HCC risk in cirrhosis.